Connect with us

National

Regeneron suspends Covid-19 antibody trial among sickest patients – Macau Business

US biotech firm Regeneron on Friday said it was suspending enrollment for a study of its Covid-19 antibody treatment among the sickest patients

Published

on

US biotech firm Regeneron on Friday said it was suspending enrollment for a study of its Covid-19 antibody treatment among the sickest patients who require high-flow oxygen or are on ventilators.
The move follows a recommendation from an independent data monitoring committee (IDMC) which assesses the results and advises when it’s necessary to halt a study.
“Based on a potential safety signal and an unfavorable risk/benefit profile at this time, the IDMC recommends further enrollment of patients…

Click here to view the original article.